Longevity Biomedical (Longevity Biomedical) Debt-to-Equity : 0.00 (As of . 20)

View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Debt-to-Equity?

Longevity Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's Total Stockholders Equity for the quarter that ended in . 20 was $0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Longevity Biomedical's Debt-to-Equity or its related term are showing as below:

LBIO's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Longevity Biomedical Debt-to-Equity Historical Data

The historical data trend for Longevity Biomedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Debt-to-Equity Chart

Longevity Biomedical Annual Data

Trend

Debt-to-Equity

Longevity Biomedical Semi-Annual Data

Debt-to-Equity

Competitive Comparison of Longevity Biomedical's Debt-to-Equity

For the Biotechnology subindustry, Longevity Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Debt-to-Equity falls into.

Longevity Biomedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Longevity Biomedical's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/	N/A
	=	N/A

Longevity Biomedical's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/
	=	N/A

Longevity Biomedical (NAS:LBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Longevity Biomedical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Biomedical (Longevity Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011

Website

https://www.longevitybiomedical.com

Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines